ABSTRACT
USAGE OF INTRAMAMMARY ANTIMICROBIAL VETERINARY MEDICINAL PRODUCTS IN THE REPUBLIC OF SERBIA FROM 2011 TO 2014
dairy products such as cheese and yogurt. Therefore, the judicious use of antimicrobials in food-producing animals, compliance with prescribed withdrawal periods and strict monitoring of drug residues are essential for the safety of both humans and animals.
In this paper, we presented the quantities of intramammary antibiotics sold in the Republic of Serbia. Furthermore, we estimated the number of cows treated with these medicines and compared this number with the reported total number of cows.
MATERIALS AND METHODS
The Medicines and Medical Devices Agency of Serbia annually collects information on medicinal sales from Marketing Authorization Holders. Those quantities are presented according to ATCvet classification of the World Health Organization (11) . A review of such information for 2014, prepared for the general public, is available on the Agency's website (12) .
ATCvet classification has become the gold standard for international drug utilization research. It classifies active substances according to system organ class, therapeutic indication and chemical properties. The European Medicines Agency published the Principles on assignment of defined daily dose for animals (DDDvet) in 2015 and defined the course dose for animals (DCDvet) (13) . Since DDDvet and DCDvet are technical units, they are intended for the investigation of medicinal consumption. When medicinal products are used during lactation, they are used for the treatment of the affected quarter, and the treatment lasts for two to four days; therefore, such products have been assigned only with DDDvet. When intramammary medicines are administered at dry-off, they are administered concomitantly into all quarters as a single treatment, and they have been assigned with DCDvet only. However, we chose not to present our findings in accordance with these principles because we could not calculate the number of animals exposed to intramammary antimicrobials in the Serbian market in such a manner. DDDvet and DCDvet are calculated on the basis of the usual posology for certain active substances and do not reflect individual variations in authorized posology for medicines containing the same active substances. Therefore, we used data from authorized Summaries of Product Characteristics for each of these products and calculated the number of treatments. On the basis of these data, we estimated the number of cows exposed to intramammary antimicrobial treatment and compared those figures with the total number of cows in the Republic of Serbia, as reported by the Statistical Office of the Republic of Serbia (14) . In this way, we could determine the approximate number of treated cows for a certain year, reducing possible errors arising from variations in posology to a minimum. All calculations were performed in Microsoft Office Excel 2007.
INTRODUCTION
People, animals, and the environment represent an interconnected, dynamic system. One health initiative aims towards better understanding and addressing contemporary health issues created by the convergence of humans, animals, and environmental domains (1) . Antimicrobial medicinal products are essential for treating infections in both humans and animals. Globally, an estimated 50% of all antimicrobials are used in veterinary medicine. Additionally, in animals antibiotic use is the primary contributor to the selection and spread of antimicrobial resistance. Animals and humans share the same antibiotic resistance mechanisms (2) . Antimicrobial resistance is regarded as one of the major threats to the future health of individuals and populations, and national and international organizations have repeatedly underlined an urgent need for action (3) . It is essential to monitor trends in the consumption of antibiotics to identify the risk factors that contribute to the spreading of the resistance (4).
Mastitis is a major challenge to the worldwide dairy industry (5) . Modern farming practice widely employs intramammary antimicrobial medicines in dairy production since intramammary infections are one of the most common conditions in bovine species (6) . Mastitis is an inflammation of the mammary gland, usually caused by pathogenic microorganisms (7). The disease is followed by a complex series of events leading to reduced synthetic activity, compositional changes, and elevated somatic cell count, all affecting milk production and quality. Escherichia coli and Streptococcus uberis are the microorganisms most frequently isolated in bovine mastitis (5) .
Intramammary antibiotics are used both for the treatment and prevention of mastitis in cattle. In cows with clinical mastitis, the treatment outcome depends on the host, bacterial and management factors as well as on the selected antimicrobial medicine (8) . When used for mastitis treatment, immediate release formulations are administered during lactation. Such medicines are administered only into the affected teat, and milk should be discarded during a brief time period, usually for several days. In contrast, long-acting formulations are administered during the dry period into all quarters. These medicines are used as a prophylactic treatment of mastitis in herds where subclinical mastitis is present. Long-acting preparations have long withdrawal periods, which can last as long as 60 or more days, depending on the time between dry-off and calving.
Allergy to antimicrobial medicines, especially to β-lactams, is a well-established adverse effect in human medicine. Sensitive persons can be exposed to antimicrobials through food, especially milk and dairy products (9) . Not only does this instigate a human health hazard, but the residues of antimicrobial medicines in milk can be a problem in the dairy industry (10) since antibiotics disable the fermentation of microorganisms used in manufacturing of
RESULTS
From 2011 to 2014, in the Republic of Serbia, there were between 19 and 25 intramammary antimicrobial medicines with Marketing Authorization (15,16). In the same time period, there were between 451,000 and 509,000 cows in the Republic of Serbia (Table 1 ). Figure 1 The number of treatments per ATCvet group is presented in Figure 4 . Beta-lactams, used as a single agent or in combination with other substances, were the most used intramammary products in the Republic of Serbia. In 2014, 80,927 cows were treated with beta-lactams in combination with other substances (ATCvet code QJ51RV). Sulphonamides and trimetoprim were the least used intramammary antibiotics, with only 119 treatments in 2013 and 952 treatments in 2014. Macrolides and lincosamides were also infrequently used, with 103 treatments in 2011, increasing to 1626 treatments in 2014.
DISCUSSION
As our research showed, up to 25% of cows in the Republic of Serbia were treated with intramammary antibiotics over one year. Most of those antibiotics were beta-lactams, whose sensitizing potential is well known. Therefore, prudent use of intramammary antimicrobials is necessary for preserving the health of both animals and humans.
Finding that beta-lactams are the most commonly used intramammary products in the Republic of Serbia was in line with findings from the Danish Integrated Antimicrobial Resistance Monitoring and Research Program (DANMAP) (4), whose report stated that beta-lactamathat variation in the number of treatments between 2012 and 2013 was the result of variation in the sales of products used during lactation and not in the dry period.
As presented in Figure 3 , the percentage of cows treated with intramammary antibiotics compared to the total number of cows in the Republic of Serbia varied between 15% and 25%. This meant that possibly 15% to 25% of milk might contain residues resulting from administration of intramammary antibiotics. This is not the final percentage because a number of animals received parenteral antimicrobial treatment. The percentage of cows treated during the dry period was approximately 5% over the first three As shown in Figure 1 , the number of sold packages varied greatly. This variation could be explained by the fact that Marketing Authorization holders report the number of sold packages of medicinal products to the Medicines and Medical Devices Agency of Serbia on a yearly basis. Larger quantities of medicinal product sold during one year might be the cause of smaller quantities of the same medicinal product sold during the next year. These differences can be observed for 2012 and 2013, when large quantities were on the market in 2012, followed by significantly smaller quantities in 2013.
It was also shown that beta-lactam antibacterials (ATCvet group QJ51C) were the most frequently used intramammary antibiotics in 2011 and 2012, which significantly differs from data for 2013 and 2014, when most packages sold were from group QJ51RV, combinations of antibacterials and other substances. Those other substances are usually steroidal hormones used to reduce inflammation. The reason for this switch from beta-lactams to combination therapies is likely due to because one large domestic manufacturer discontinued the manufacturing of veterinary medicines, including intramammary ones, and other medicine manufacturers took over the market.
Furthermore, the number of sold packages does not reflect the number of treated cows since some medicinal packages contain 20 or more intramammary injectors and others contain a single injector in the package. The posology also differs, and such information is available in the Summary of Product Characteristics (SmPC) for each registered product. For that reason, to determine the exposure of the animal population to intramammary antibiotics, it was necessary to calculate the number of treated cows to estimate the exposure of animals to such medicines. However, these figures are not final and represent only an approximate value since they are based on medicinal quantities reported by Marketing Authorization Holders. Collecting data from veterinary institutions and end users could provide more accurate information on medicine usage.
These results provide important information about exposure of cattle to certain antibiotics and, therefore, direct future research towards investigating a linkage between antibiotic resistance and administration of intramammary veterinary medicinal products. Beta-lactams are the most frequently used intramammary antimicrobials in the Republic of Serbia and, therefore, their residues represent a major concern that needs to be closely monitored and further investigated.
